Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 25, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: BRRY) ("DelMar") today announced the successful acquisition (the "Acquisition"), through a share exchange agreement, of all of the outstanding shares of Del Mar Pharmaceuticals (BC) Ltd., a clinical and commercial stage drug development company with a focus on the treatment of cancer.  Concurrent with the Acquisition, DelMar completed the first closing in a private placement consisting of approximately 6.7 million units of its securities to qualified accredited investors, for total gross proceeds of approximately $5.4 million.

DelMar will be quoted on the OTC QB under the symbol "BRRY" beginning January 25th, 2013; the symbol will be changed to "DMPI" on or about January 31, 2013.

Charles Vista LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.

"DelMar is pleased to achieve this important milestone," stated Jeffrey Bacha , Chief Executive Officer of DelMar. "Becoming a publicly traded company will allow for broad and diversified investor exposure and access to the capital markets.  These funds will position us to expand and accelerate our drug development activities with our lead drug candidate, VAL-083.  Our company and our management are committed to creating shareholder value by executing on our mission to rapidly develop and commercialize proven cancer therapies in new orphan drug indications in areas of significant unmet medical need, particularly where patients have failed modern targeted medicines."

VAL-083, represents a "first in class" small-molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calabasas, CA (PRWEB) July 10, 2014 ... academic institutions and professional associations, addressed the challenges of ... & Medical Device Industries” through strategic sourcing. Describing the ... ) with the Supply Chain Management Institute ( SCMI) ... the event on June 24 at the Kroc Institute ...
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... with headquarters in Madison, said it has agreed to trade ... ,In exchange for acquiring most of the customers Integra Telecom ... Fargo and Grand Forks in North Dakota, and Little Falls, ... state approval, the deal is expected to close within 90 ...
... Cub Foods' three stores in the Madison area installed fingerprint ... of the finger and at lower cost to the ... in the supermarket's computers that includes payment information. Pay By ... the payments cost retailers 12 cents each, versus an average ...
... national economic development assessment group for its high quality of ... for the States, released last week by the non-profit Corporation ... and Bs in business vitality and development capacity, based on ... in the subcategories that made up those three overall marks. ...
Cached Biology Technology:
(Date:7/10/2014)... , July 9, 2014 The widespread ... in large part by meaningful use and related ... providers interact with laboratory information. Now, more than ... field of clinical informatics in order to deliver ... To address the educational needs of pathologists in ...
(Date:7/10/2014)... vegetable oil found in your popcorn or soap might not ... even worse, according to an analysis in the Cell Press ... growing demand for vegetable oil has already led to the ... trouble for orangutans in particular. If guidelines are not put ... large-scale industrial plantations from Asia into Africa will be bad ...
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) ... of Medicine today announced they will be partnering ... anti-cancer drugs. , Under the agreement with Shanghai-based ... share the costs and risks of discovery and ... jointly own any intellectual property and commercialization rights ...
Breaking Biology News(10 mins):New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4Hunger for vegetable oil means trouble for Africa's great apes 2Marshall University to partner with international company in drug development venture 2
... closer to an effective HIV vaccine. Researchers from ... and the Ragon Institute of MGH, MIT and ... neutralizing antibodies, which block HIV infection. Details are ... PLoS Pathogens . According to author Leo ...
... has designated 2011 the "International Year of Chemistry (IYC)" ... to the world around us. This worldwide initiative is ... Educational, Scientific and Cultural Organization (UNESCO) and the International ... activities conducted by countries, such as the United States, ...
... Six researchers from LSU,s College of Science have been ... for the Advancement of Science, or AAAS, the world,s largest ... ranks LSU among the top 10 percent of universities with ... more than 220 institutions worldwide. LSU ranked second in the ...
Cached Biology News:Researchers report on the early development of anti-HIV neutralizing antibodies 2US launches International Year of Chemistry Feb. 1 with panel of world-renowned chemists 26 LSU College of Science faculty named AAAS Fellows 2
TXNL2 Antibody...
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Biology Products: